Evidence map›Paper›PMID 25185891›Full record

ArticleMacromolecular bioscience2014

In vitro synergistic action of geldanamycin- and docetaxel-containing HPMA copolymer-RGDfK conjugates against ovarian cancer.

Nate Larson, Sarah Roberts, Abhijit Ray, Brandon Buckway, Darwin L Cheney, Hamidreza Ghandehari

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Macromolecular bioscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Polymer nanomedicines.Advanced drug delivery reviews · 2020
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Nate LarsonTheraTarget, Inc., 615 Arapeen Dr., Suite 302-Y, Salt Lake City, UT, 84108, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, Center for Nanomedicine, Nano Institute of Utah, Salt Lake City, UT, 84112, USA.
Sarah Roberts
Abhijit Ray
Brandon Buckway
Darwin L Cheney
Hamidreza Ghandehari
TheraTarget (United States) · USNanotherapeutics (United States) · USUniversity of Utah · US

Funding

Polymers for Targeted Delivery of Angiogenic InhibitorsR01EB007171 · NIBIB · UNIVERSITY OF UTAH · PI GHANDEHARI, HAMID · 2006 to 2009
$1.1M
Targeted Polymeric Combination Delivery for Treatment of Ovarian CancerR41CA144818 · NCI · THERATARGET · PI GHANDEHARI, HAMID · 2010 to 2010
$100k
NCI NIH HHS R41 CA144818NCI NIH HHS R41CA144818NIBIB NIH HHS R01 EB007171NIBIB NIH HHS R01EB007171
6 · The paper itself

Abstract

HPMA copolymer-RGDfK (HPMA-RGDfK) conjugates bearing either aminohexylgeldanamycin (AHGDM) or docetaxel (DOC) were synthesized and characterized. In vitro stability and binding were evaluated. Cytotoxicity toward ovarian cancer cells was evaluated and the ability of the conjugates to induce cell death was assessed by combination index analysis. Conjugates bearing AHGDM were more stable and exhibited slower drug release than those bearing DOC. Both conjugates demonstrated the ability to bind to avb3 integrins. In combination, HPMA-RGDfK conjugates demonstrated marked synergism as compared to their non-targeted counterparts and free drug controls. HPMA-RGDfK conjugates bearing AHGDM and DOC induce synergistic cytotoxicity in vitro, suggesting their potential as a promising combination therapy.

Indexed as

Antibiotics, AntineoplasticBenzoquinonesLactams, MacrocyclicMethacrylatesOligopeptidesTaxoidsCell DeathCell Line, TumorDocetaxelDrug Screening Assays, AntitumorFemaleHumansIntegrin alphaVbeta3Ovarian NeoplasmsAntibiotics, Antineoplasticarginyl-glycyl-aspartic acidBenzoquinonesDocetaxelgeldanamycinhydroxypropyl methacrylateIntegrin alphaVbeta3Lactams, MacrocyclicMethacrylatesOligopeptidesTaxoidsdocetaxelgeldanamycinovarian cancertargeted drug delivery

Identifiers

PMID25185891
PMCPMC4262670
OpenAlexW1948259779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.